Rockefeller Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Rockefeller Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506K	Sell	19,306 -291	-1%	-$6.78K	﹤0.01%	2081
2026 Q1	$462K	Sell	19,597 -31,988	-62%	-$816K	﹤0.01%	2018
2025 Q4	$1.5M	Buy	51,585 +12,646	+32%	+$324K	﹤0.01%	1376
2025 Q3	$734K	Buy	38,939 +17,845	+85%	+$281K	﹤0.01%	1581
2025 Q2	$296K	Buy	21,094 +2,637	+14%	+$37K	﹤0.01%	1653
2025 Q1	$289K	Buy	+18,457	New	+$260K	﹤0.01%	1599
2021 Q2	–	Sell	-1,000	Closed	-$28K	–	3432
2021 Q1	$28K	Hold	1,000	–	–	﹤0.01%	2124
2020 Q4	$28K	Buy	+1,000	New	+$24.5K	﹤0.01%	1871

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rockefeller Capital Management's ARQT Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 1.5% in Q2 2026, selling an estimated $6.78K and leaving 19,306 shares worth $506K. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Rockefeller Capital Management first reported a position in ARQT in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.5M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Rockefeller Capital Management held 19,306 shares of Arcutis Biotherapeutics worth $506K as of Q2 2026.
Rockefeller Capital Management sold 291 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.78K.
Arcutis Biotherapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2081 holding.
Rockefeller Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 8 quarters since.
Rockefeller Capital Management's Arcutis Biotherapeutics position peaked at $1.5M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.